Life Science Lead Generation: The Complete Playbook

How to build consistent biotech and pharma pipeline: deliverability, ICP definition, signal-based outreach, cold email that scientists read, and what to measure. From practitioners who've run 1,000,000+ emails.

By Harrison Waid

Most Life Science Lead Generation Fails Before the First Email Is Sent

Ask a VP of Sales at a life science vendor why their pipeline is thin and you'll hear one of three answers: "our market is small," "relationships drive everything in this space," or "we need to hire more SDRs."

None of these are wrong exactly. But they're all being used as explanations for a fixable problem.

The market isn't too small. It's under-targeted. Most life science companies have an ICP that's too broad to generate quality pipeline and too narrow to scale without burning it out. Finding the right 200 accounts is more valuable than having access to 10,000 vaguely relevant ones.

Relationships do drive a significant amount of life science revenue. They don't replace pipeline generation. They reward it. The companies with the best relationships built them through systematic contact over time, not through luck.

More SDRs doesn't fix broken messaging or misaligned targeting. It scales the problem.

This guide covers what actually works across the full pipeline generation process: infrastructure, targeting, messaging, sequencing, and measurement. It's built from patterns we've seen across 100+ clients, 2000+ outbound campaigns, and sending 1,000,000+ emails into biotech, pharma, CROs, CDMOs, and research institutions.

Part 1: Deliverability — Fix This First or Nothing Else Matters

Most sales teams assume their outbound emails are being seen. They're not. A significant portion of cold outreach in life science never reaches the primary inbox — it hits spam, promotions, or gets soft-bounced entirely. Teams often don't notice because surface-level metrics like opens and clicks still look roughly healthy. What they're actually measuring is how well their emails are passing spam filters, not whether they're generating real buyer engagement.

Here's the core problem: many cold outreach programs are built on shared domains or sending infrastructure with degraded reputation. Sending at high volume from day one accelerates this. Microsoft Outlook and Google Workspace have both significantly strengthened their spam filtering in recent years. If your sequences are going into Outlook inboxes at pharma and biotech companies (which they almost certainly are) the deliverability landscape is harder than it was 18 months ago.

The result: you're not testing your messaging or your ICP. You're testing spam filters. When results are poor, teams assume the message or the list is wrong and go back to the drawing board. Sometimes that's right. Often the problem is upstream. What good infrastructure looks like:

Dedicated sending domains (not your primary company domain). Multiple domains, each with controlled sending volume. Active inbox warming before campaigns go live. Strict daily sending limits per inbox. Constant monitoring of bounce rates, spam complaints, and reply rates as health signals.

At Succession, we don't track open rates for this reason. Bots trigger a significant portion of opens, particularly in enterprise email environments. Tracking them creates false signals and, worse, using open tracking pixels increases the likelihood of landing in spam in the first place. We measure replies, positive replies, and meetings booked. Those are the metrics that reflect real buyer behaviour.

If you're running cold outreach in-house and haven't audited your sending infrastructure recently, start there before touching anything else.

Further reading: #060: Sending to Outlook — what changed with Microsoft's spam filters and what to do about it.

Part 2: The Real Problem With Life Science Outreach (It's Not Search Intent)

Here's a framing issue that catches a lot of companies out.

Your buyers — scientists, heads of R&D, VP of BD at a pharma company, lab director at a CRO — are not Googling for what you sell. If you make a novel assay reagent, they're not typing "novel assay reagent for X application" into Google. If you run a specialist CRO service, they're not searching for your category. Especially if your technology is genuinely new, the terminology for what you do may not even be an established search term yet.

This means inbound-only strategies leave the majority of your market unreachable. The buyer with the problem you solve doesn't know to look for you. They discover you when you reach out at the right moment, via a referral from a trusted contact, or through consistent presence in the spaces they pay attention to — industry publications, conferences, LinkedIn from someone they know.

This is not a weakness of your product. It's the nature of the market. Novel technology sells on explanation, not search. The implication is that proactive outbound isn't optional in life science — it's the primary way to generate new pipeline.

The secondary implication: your messaging has to do all the educating that a search click and a landing page do in a more mature category. You're introducing the problem AND the solution in the same outreach. That's a harder job than it sounds.

Part 3: ICP — The Foundation Everything Else Depends On

Most life science lead gen programs have an ICP that's too broad to work. "Biotech and pharma companies" describes a market, not a customer. You cannot build a targeted list, write relevant messaging, or identify buying triggers from a description that includes 50,000 potential companies globally.

A useful ICP narrows to the point where a data provider can build you a list and a rep can immediately recognize whether an account belongs on it.

Company-level filters: The targeting mistake specific to life science: using job title and company size as the primary filters. As Divya wrote in The 5 Challenges of Life Sciences Lead Generation: "Two people with the same title may operate in completely different scientific, technical, and organisational contexts. A senior scientist at a small biotech is often doing a bit of everything — running experiments, assessing tools, influencing purchasing decisions. A senior scientist in big pharma operates in a much more narrowly defined role with decision-making distributed across multiple layers." Same title. Completely different buying context.

The fix is targeting around scientific and organisational context: what teams are actually working on, what methods they use, what problems they're actively trying to solve. This is harder to build but generates dramatically better conversion.

Practical ICP exercise: Take your last 10 won clients. For each one, identify: what was happening at that company in the 90 days before they first engaged with you? What was the situation that made them open to the conversation? The answer to that question is your real ICP trigger, and it's more valuable than any demographic filter.

Part 4: Messaging — The 10 Questions Your Email Has to Answer

Getting your email opened, read, and replied to requires answering a specific sequence of questions the prospect asks themselves, mostly unconsciously. Miss any of them and the chain breaks.

This framework comes from our 4P Email Framework, which we've been testing and refining across hundreds of life science campaigns.

To get the email delivered: Is your sending infrastructure clean? Dedicated domain, warmed inbox, controlled volume. Covered above. To get the email opened: Three questions the prospect asks: Who is sending this? What's the subject line? What's in the preview text? If they've never heard of you, the subject line and preview text have to do the entire job. A short subject line leaves more space for preview text — use it. The first sentence of your email is the preview text on most email clients. If it starts with "I hope this finds you well" or goes straight into product pitch, it signals "sales email, delete." To get the email read: Three more questions: How long will this take? Is this about me? Why should I read the next line? Under 125 words. Under 100 if you can. Every line has to earn the next. If your first line is personalised and relevant, they'll read the second. If the second calls out a problem they recognise, they'll read the third. To get a reply: Could this help me? Is it worth responding? What are they asking for? Soft CTAs get 30% more replies than asking for a meeting — we've seen this consistently in life science outreach. "Interested in learning more?" gets more replies than "Can we schedule a 30-minute call?" Once a conversation has started, you can ask for the meeting. The 4P structure in practice:

Example of what this looks like in life science:

I noticed your team recently published on CAR-T manufacturing scale-up. The yield variability issue you described in the methods section is something we see come up constantly in similar programs. We've developed a process monitoring approach that's been cutting that variance by around 30% in comparable workflows. Would it be useful to share what we're seeing?

Personalised. Problem called out specifically. Proposed solution stated as a hypothesis. Prompt is a question, not a meeting request. Under 75 words.

For more on calibrating technical depth: How Technical Should Your Prospecting Emails Really Be? covers the balance between sounding credible and overwhelming your reader. The short version: enough technical specificity to signal "I understand your world," not enough to feel like a methods section.

Part 5: Signal-Based Outreach — Reaching the Right People at the Right Moment

The best time to contact a prospect is when something in their world has just changed. Trigger-based outreach is relevance-by-default: you're reaching out because something happened, which makes the conversation easier to justify and easier to open.

In life science, the most reliable triggers are:

Funding events: A Series A or B close at a biotech usually precedes a commercial buildout by 6 to 12 months. The company is about to hire sales, BD, and commercial leadership. They're evaluating vendors and service providers they didn't need before. This is your window. Key commercial hires: A biotech that just posted a VP of Sales or Head of BD role is signalling it's building out commercial capabilities. They need tools and services that commercial teams use. Pipeline milestones: IND filing, Phase 1 initiation, Phase 2 data readout. Each of these unlocks a new set of commercial decisions. The timing matters more than the milestone itself. Conference activity: Poster presentations, conference talks, published abstracts. These tell you what a team is actively working on and give you a specific, recent reference point for outreach. Published papers: If a team publishes work that intersects with what you solve, they've told you exactly what they're doing without you having to guess. Hiring signals broadly: Job postings for specific technical roles tell you what problems a company is trying to solve. A biotech hiring three analytical chemistry positions is almost certainly scaling up a process. If you sell process analytics tools, that's your trigger.

The operational challenge is that monitoring these signals manually doesn't scale. Most teams either ignore triggers entirely and do list-based outreach, or they pay for signal monitoring tools and then fail to integrate those signals into their sequences. Building the workflow that connects trigger to message to send is where the real ROI lives.

For 27 specific campaign ideas that use these triggers: 27 Campaign Ideas for 2026.

Part 6: Sequences — One Email Is Not a Campaign

Single-touch outreach generates negligible pipeline in any market. In life science, where buying cycles are long and scientific buyers are selective about what they respond to, a single email that doesn't land at exactly the right moment is simply gone.

Effective sequences:

On the LinkedIn component: connecting before you email increases the likelihood your email is recognised and opened. Not by a huge margin, but every bit of familiarity helps in a cold outreach context.

The "breakup email" — the final touchpoint that explicitly says "I won't reach out again unless you want me to, but if the timing changes, here's how to find us" — consistently generates responses from prospects who didn't engage with earlier messages. Something about the finality of it prompts a reply.

One thing to avoid: treating a follow-up sequence as an opportunity to repeat yourself at decreasing intervals. Each follow-up needs a reason to exist — a new data point, a case study relevant to something happening in their space, a question that's different from the first one. "Just following up" tells the prospect you have nothing new to say.

Part 7: The SDR Decision

Build in-house: Best when you have management bandwidth to hire, ramp, and coach SDRs. A life science SDR with no prior industry experience typically takes 4 to 6 months to generate consistent qualified pipeline. You need a playbook, a target list, and someone who can listen to calls and improve messaging week by week. Without these, you're paying for expensive ramp time with unpredictable output. Outsource: Best when you need pipeline faster than you can hire and ramp, when you're testing a new ICP before committing to a headcount, or when your in-house outbound isn't generating pipeline at the cost it should. The critical variable: the provider needs to understand life science specifically. Generic B2B agencies don't know how scientific buyers think, which personas matter at different company types, or how to calibrate technical depth in messaging. The output shows. The hybrid: Many life science vendors run outsourced outbound to generate pipeline while building in-house capability in parallel. When the in-house program is producing pipeline at comparable cost, they transition. This avoids the gap between "we decided to hire" and "we have qualified pipeline."

Part 8: Metrics That Actually Matter

This was covered briefly in the 5 Challenges piece but it's worth being specific, because the wrong metrics drive the wrong behaviours.

What to measure: What to stop measuring:

The practical benchmark across well-targeted life science outbound: 3 to 6% positive reply rate on email for a well-defined ICP with relevant messaging. Below that, something is broken in the infrastructure, the list, or the message. Significantly below that, it's usually deliverability.

If you're measuring opens and seeing 40%+ but replies are under 1%, you have a deliverability problem. Bot activity or Outlook's auto-preview feature is triggering open tracking. The emails are technically "opening" in an automated environment, not being read by a human.

What Good Looks Like

The life science lead gen programs that consistently perform share a few characteristics:

Their sending infrastructure is treated like an asset, not an afterthought. Domains are dedicated, warmed, and monitored constantly.

Their targeting is specific enough to be relevant. Not "life science companies" — a defined segment with a defined problem at a defined stage.

Their messaging is personalised at the point of research, not at the point of send. The personalisation that gets replies is specific to the individual and their current situation, not a mail merge field with their company name.

They measure the right things. Positive reply rate. Meetings. Pipeline. Not opens.

They treat the sequence as a system, not a one-shot attempt. Every touchpoint has a reason to exist. The overall sequence has a beginning and an end.

Going Deeper

These blog posts go deeper on specific elements of what's covered here:

How Succession Fits

We run outbound lead generation programs for companies selling into biotech, pharma, CROs, CDMOs, and research institutions. We build the list, write the messages, manage the infrastructure, run the sequences, and book qualified meetings directly on your calendar.

If you want to know whether your current outbound is fixable in-house or whether outsourcing makes sense, book a strategy call. We'll give you a straight answer either way.

Succession Bio helps life science vendors, instrument companies, CROs, and service providers build outbound programs that generate qualified meetings with biotech and pharma buyers.